Jörg Kraus

2.6k total citations
102 papers, 1.7k citations indexed

About

Jörg Kraus is a scholar working on Pathology and Forensic Medicine, Neurology and Immunology. According to data from OpenAlex, Jörg Kraus has authored 102 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pathology and Forensic Medicine, 24 papers in Neurology and 21 papers in Immunology. Recurrent topics in Jörg Kraus's work include Multiple Sclerosis Research Studies (45 papers), Peripheral Neuropathies and Disorders (11 papers) and Immunotherapy and Immune Responses (11 papers). Jörg Kraus is often cited by papers focused on Multiple Sclerosis Research Studies (45 papers), Peripheral Neuropathies and Disorders (11 papers) and Immunotherapy and Immune Responses (11 papers). Jörg Kraus collaborates with scholars based in Austria, Germany and United States. Jörg Kraus's co-authors include Patrick Oschmann, Britta Engelhardt, Stefan Hamm, Frank Duffner, Stefan Liebner, Gesa Rascher-Eggstein, Karen Wolburg‐Buchholz, Werner Risau, Hartwig Wolburg and Johann Sellner and has published in prestigious journals such as Neurology, Stroke and Annals of Neurology.

In The Last Decade

Jörg Kraus

99 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jörg Kraus Austria 21 549 443 349 330 294 102 1.7k
Erin E. Longbrake United States 20 860 1.6× 365 0.8× 286 0.8× 404 1.2× 281 1.0× 58 1.6k
Barbara Tucky United States 22 517 0.9× 673 1.5× 357 1.0× 809 2.5× 182 0.6× 29 2.1k
Alice Laroni Italy 25 838 1.5× 242 0.5× 494 1.4× 835 2.5× 342 1.2× 52 2.4k
Kurt‐Wolfram Sühs Germany 25 574 1.0× 166 0.4× 366 1.0× 163 0.5× 462 1.6× 77 1.6k
Eroboghene E. Ubogu United States 27 202 0.4× 526 1.2× 314 0.9× 338 1.0× 574 2.0× 72 2.0k
Merja Soilu‐Hänninen Finland 27 1.2k 2.2× 173 0.4× 345 1.0× 600 1.8× 372 1.3× 72 2.2k
S. Michalak Poland 20 289 0.5× 134 0.3× 353 1.0× 412 1.2× 340 1.2× 149 1.7k
Arnon Karni Israel 26 846 1.5× 494 1.1× 449 1.3× 723 2.2× 497 1.7× 92 2.6k
Saud Sadiq United States 32 483 0.9× 289 0.7× 880 2.5× 351 1.1× 971 3.3× 85 2.8k
John Lindsey United States 22 730 1.3× 115 0.3× 311 0.9× 478 1.4× 394 1.3× 68 1.5k

Countries citing papers authored by Jörg Kraus

Since Specialization
Citations

This map shows the geographic impact of Jörg Kraus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Kraus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Kraus more than expected).

Fields of papers citing papers by Jörg Kraus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Kraus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Kraus. The network helps show where Jörg Kraus may publish in the future.

Co-authorship network of co-authors of Jörg Kraus

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Kraus. A scholar is included among the top collaborators of Jörg Kraus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Kraus. Jörg Kraus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ponleitner, Markus, Nik Krajnc, Tobias Zrzavy, et al.. (2025). Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR). Journal of Neurology. 272(12). 774–774.
2.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2024). Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria. Journal of Neurology. 271(6). 3142–3152. 2 indexed citations
3.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2023). Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria. Journal of Neurology. 270(6). 3103–3111. 2 indexed citations
4.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2021). Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry. Journal of Neurology. 268(11). 4303–4310. 12 indexed citations
5.
Moser, Tobias, Ciara K. O’Sullivan, Georg Pilz, et al.. (2021). Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy. Biomedicines. 9(11). 1584–1584. 10 indexed citations
6.
Pilz, Georg, Peter Wipfler, Jörg Kraus, et al.. (2020). Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction. Fluids and Barriers of the CNS. 17(1). 7–7. 21 indexed citations
7.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2019). Real‐life use of oral disease‐modifying treatments in Austria. Acta Neurologica Scandinavica. 140(1). 32–39. 9 indexed citations
8.
Dal‐Bianco, Assunta, Paulus Rommer, Michael Weber, et al.. (2018). Do elevated autoantibodies in patients with multiple sclerosis matter?. Acta Neurologica Scandinavica. 139(3). 238–246. 6 indexed citations
9.
Harrer, Andrea, Georg Pilz, Katrin Oppermann, et al.. (2017). From natalizumab to fingolimod in eight weeks — Immunological, clinical, and radiological data in quest of the optimal switch. Clinical Immunology. 176. 87–93. 4 indexed citations
10.
Broussalis, Erasmia, Alexander Kunz, Monika Killer‐Oberpfalzer, et al.. (2017). Late age onset of amyotrophic lateral sclerosis is often not considered in elderly people. Acta Neurologica Scandinavica. 137(3). 329–334. 8 indexed citations
11.
Guger, Michael, Christian Enzinger, Fritz Leutmezer, et al.. (2017). Real‐life clinical use of natalizumab and fingolimod in Austria. Acta Neurologica Scandinavica. 137(2). 181–187. 22 indexed citations
12.
13.
Broussalis, Erasmia, Eugen Trinka, Jörg Kraus, Mark R. McCoy, & Monika Killer‐Oberpfalzer. (2013). Treatment strategies for vasculitis that affects the nervous system. Drug Discovery Today. 18(17-18). 818–835. 9 indexed citations
14.
Reuß, Reinhard, et al.. (2013). TRAF2 is Upregulated in Relapsing-Remitting Multiple Sclerosis. NeuroImmunoModulation. 20(3). 177–183. 11 indexed citations
15.
Kunz, Alexander, Jörg Kraus, Peter Young, et al.. (2012). Biomarkers of Inflammation and Endothelial Dysfunction in Stroke with and without Sleep Apnea. Cerebrovascular Diseases. 33(5). 453–460. 25 indexed citations
16.
Killer‐Oberpfalzer, Monika, Eugen Trinka, Jörg Kraus, & Erasmia Broussalis. (2011). Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy. Expert Opinion on Drug Discovery. 6(4). 353–369. 1 indexed citations
17.
Pilz, Georg, Peter Wipfler, G. Ladurner, & Jörg Kraus. (2008). Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discovery Today. 13(23-24). 1013–1025. 17 indexed citations
18.
Kraus, Jörg & Patrick Oschmann. (2006). The impact of interferon-β treatment on the blood–brain barrier. Drug Discovery Today. 11(15-16). 755–762. 45 indexed citations
19.
Kraus, Jörg, et al.. (2004). Interferon‐β stabilizes barrier characteristics of brain endothelial cells in vitro. Annals of Neurology. 56(2). 192–205. 87 indexed citations
20.
Laske, Christoph, Patrick Oschmann, Thomas Bregenzer, et al.. (2001). Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Acta Neurologica Scandinavica. 103(2). 105–113. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erin E. Longbrake Breakdown of academic impact, for papers by Barbara Tucky Breakdown of academic impact, for papers by Alice Laroni Breakdown of academic impact, for papers by Kurt‐Wolfram Sühs Breakdown of academic impact, for papers by Eroboghene E. Ubogu Breakdown of academic impact, for papers by Merja Soilu‐Hänninen Breakdown of academic impact, for papers by S. Michalak Breakdown of academic impact, for papers by Arnon Karni Breakdown of academic impact, for papers by Saud Sadiq Breakdown of academic impact, for papers by John Lindsey
Rankless by CCL
2026